WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001025435) IN VIVO TREATMENT OF JOINT DISEASE USING INTERLEUKIN-1 RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/025435    International Application No.:    PCT/US2000/040823
Publication Date: 12.04.2001 International Filing Date: 06.09.2000
Chapter 2 Demand Filed:    30.03.2001    
IPC:
A61K 38/20 (2006.01), A61K 48/00 (2006.01)
Applicants: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION [US/US]; P.O. Box 483, Fort Collins, CO 80521 (US) (For All Designated States Except US).
FRISBIE, David, D. [US/US]; (US) (For US Only).
MCILLWRAITH, C., Wayne [US/US]; (US) (For US Only)
Inventors: FRISBIE, David, D.; (US).
MCILLWRAITH, C., Wayne; (US)
Agent: RANDS, M., Todd; Howrey Simon Arnold & White, LLP, 750 Bering Drive, Houston, TX 77057-2198 (US)
Priority Data:
60/152,707 07.09.1999 US
Title (EN) IN VIVO TREATMENT OF JOINT DISEASE USING INTERLEUKIN-1 RECEPTOR ANTAGONISTS
(FR) TRAITEMENT IN VIVO DE LA MALADIE DES ARTICULATIONS UTILISANT DES ANTAGONISTES DE RECEPTEURS D'INTERLEUKINE-1
Abstract: front page image
(EN)Adenovirus particles encoding an interleukin-1 receptor antagonist were found to be effective in treating joint disease over an extended period of time when administered directly via arthrocentesis. Administration of the adenovirus particles resulted in an increase in interleukin-1 receptor antagonist protein concentration, increased influx of white blood cells, increased percentage of neutrophils, and a lower percentage of mononuclear cells when compared to control experiments.
(FR)Des particules d'adénovirus codant un antagoniste de récepteur d'interleukine-1 sont efficaces dans le traitement longue durée de la maladie des articulations lorsqu'elles sont administrées directement par arthrocentèse. L'administration des particules d'adénovirus s'est traduite par une augmentation de la concentration de protéine antagoniste de récepteur d'interleukine-1, une augmentation de l'afflux de globules blancs, une augmentation du pourcentage de neutrophiles, et une diminution du pourcentage de cellules mononucléiques en comparaison aux expériences de contrôle.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)